HC Wainwright Expects Lower Earnings for ProQR Therapeutics

Key Points

• HC Wainwright has revised down its FY2025 earnings per share estimate for ProQR Therapeutics to ($0.45), down from ($0.41), while the consensus estimate for the current year stands at ($0.31) per share.
• ProQR Therapeutics reported a loss of ($0.14) per share for the last quarter, missing analyst expectations by ($0.06), with revenue of $4.33 million falling short of estimates of $5.01 million.
• The stock has experienced a recent trading range between a 12-month low of $1.07 and a high of $4.62, opening at $2.21 on Thursday.

ProQR Therapeutics N.V. (NASDAQ:PRQR - Free Report) - Investment analysts at HC Wainwright decreased their FY2025 earnings per share (EPS) estimates for ProQR Therapeutics in a research report issued on Monday, August 25th. HC Wainwright analyst A. Fein now anticipates that the biopharmaceutical company will post earnings per share of ($0.45) for the year, down from their prior forecast of ($0.41). The consensus estimate for ProQR Therapeutics' current full-year earnings is ($0.31) per share.

Several other equities analysts also recently issued reports on the stock. Cantor Fitzgerald reissued an "overweight" rating and set a $8.00 price objective on shares of ProQR Therapeutics in a research note on Friday, June 27th. Oppenheimer cut their price target on ProQR Therapeutics from $15.00 to $9.00 and set an "outperform" rating for the company in a report on Tuesday, May 13th. Chardan Capital reissued a "buy" rating and set a $4.00 price target on shares of ProQR Therapeutics in a research note on Friday, August 8th. Evercore ISI restated an "outperform" rating on shares of ProQR Therapeutics in a report on Friday, July 11th. Finally, JMP Securities reiterated a "market outperform" rating and issued a $8.00 target price on shares of ProQR Therapeutics in a research note on Friday, June 27th. One analyst has rated the stock with a Strong Buy rating and seven have given a Buy rating to the company. According to MarketBeat.com, ProQR Therapeutics currently has a consensus rating of "Buy" and a consensus price target of $8.00.

ProQR Therapeutics Price Performance

ProQR Therapeutics stock opened at $2.21 on Thursday. The stock has a market capitalization of $232.51 million, a P/E ratio of -4.80 and a beta of 0.43. ProQR Therapeutics has a 12-month low of $1.07 and a 12-month high of $4.62. The firm's 50-day moving average is $2.15 and its two-hundred day moving average is $1.87.

ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) last announced its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.06). The firm had revenue of $4.33 million during the quarter, compared to analyst estimates of $5.01 million. ProQR Therapeutics had a negative net margin of 238.52% and a negative return on equity of 61.25%.

Institutional Trading of ProQR Therapeutics

A number of institutional investors have recently modified their holdings of the company. Woodline Partners LP purchased a new stake in ProQR Therapeutics during the 4th quarter worth $9,426,000. Millennium Management LLC increased its stake in ProQR Therapeutics by 1,864.4% during the 4th quarter. Millennium Management LLC now owns 2,827,280 shares of the biopharmaceutical company's stock worth $7,492,000 after buying an additional 2,683,351 shares during the period. Aberdeen Group plc purchased a new stake in shares of ProQR Therapeutics during the first quarter worth about $2,461,000. Point72 Asset Management L.P. acquired a new stake in ProQR Therapeutics in the fourth quarter valued at $3,952,000. Finally, ArrowMark Colorado Holdings LLC acquired a new stake in ProQR Therapeutics during the fourth quarter valued at approximately $3,131,000. Hedge funds and other institutional investors own 32.65% of the company's stock.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.